Urothelial Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

December 14 20:16 2023
Urothelial Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)

DelveInsight’s, “Urothelial Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Urothelial Carcinoma Pipeline Report

  • DelveInsight’s Urothelial Carcinoma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
  • The leading Urothelial Carcinoma Companies working in the market include MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, and others
  • Promising Urothelial Carcinoma Pipeline Therapies in the various stages of development include Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat, and others
  • December 2023: Seagen Inc. announced a study of phase 2 clinical trials for disitamab vedotin and pembrolizumab. This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
  • On July 2023, Seagen Inc announced a study of phase 2 clinical trials for pembrolizumab and disitamab vedotin. This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
  • On July 2023, Bayer announced a study of phase 1 clinical trials for Rogaratinib (BAY1163877) and Atezolizumab. The primary objectives of this Phase 1b study (Part A) are to determine the safety, tolerability, RP2D and pharmacokinetics of rogaratinib in combination with atezolizumab in these patients.
  • On June 2023, Incyte Corporation announced a study of phase 2 clinical trials for retifanlimab, epacadostat and INCAGN02385. This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical cystectomy.

 

Request a sample and discover the recent advances in Urothelial Carcinoma Treatment Drugs @ Urothelial Carcinoma Pipeline Outlook Report

 

In the Urothelial Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Urothelial Carcinoma NDA approvals (if any), and product development activities comprising the technology, Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Urothelial Carcinoma Overview

Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer. Urothelial carcinomas are the fourth most common tumors after prostate (or breast cancer), lung and colorectal cancer. This carcinoma is derived from the urothelium of the upper urinary tract (renal pelvis and ureter) or lower urinary tract (urinary bladder).

 

Find out more about Urothelial Carcinoma Therapeutics Assessment @ Urothelial Carcinoma Preclinical and Discovery Stage Products

 

Urothelial Carcinoma Emerging Drugs Profile

  • Pemazyre (pemigatinib): Incyte
  • Cetrelimab: Janssen Research and Development

 

Urothelial Carcinoma Pipeline Therapeutics Assessment

There are approx. 40+ Urothelial Carcinoma companies which are developing the Urothelial Carcinoma therapies. The Urothelial Carcinoma companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Phase III include Janssen Research and Development.

 

DelveInsight’s Urothelial Carcinoma pipeline report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intranasal
  • Intrathecal
  • Intravenous
  • Oral
  • Oral/Intravenous
  • Parenteral
  • Subcutaneous
  • Subcutaneous/Intramuscular
  • Transdermal

 

Urothelial Carcinoma Products have been categorized under various Molecule types such as

  • Antisense oligonucleotide
  • Gene therapy
  • Hormones
  • Neuropeptides
  • Oligonucleotides
  • Small Molecule
  • Triglyceride

 

Learn more about the emerging Urothelial Carcinoma Pipeline Therapies @ Urothelial Carcinoma Clinical Trials Assessment

 

Scope of Urothelial Carcinoma Pipeline Report

  • Coverage- Global
  • Urothelial Carcinoma Companies- MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, and others.
  • Urothelial Carcinoma Pipeline Therapies- Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat, and others
  • Urothelial Carcinoma Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for new drugs for Urothelial Carcinoma Treatment, Visit @ Urothelial Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Urothelial Carcinoma Executive Summary
  3. Urothelial Carcinoma: Overview
  4. Urothelial Carcinoma Pipeline Therapeutics
  5. Urothelial Carcinoma Therapeutic Assessment
  6. Urothelial Carcinoma– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase III)
  8. Cetrelimab: Janssen Research and Development
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Vactosertib: MedPacto
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. MV NIS: Vyriad
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Urothelial Carcinoma Key Companies
  24. Urothelial Carcinoma Key Products
  25. Urothelial Carcinoma- Unmet Needs
  26. Urothelial Carcinoma- Market Drivers and Barriers
  27. Urothelial Carcinoma- Future Perspectives and Conclusion
  28. Urothelial Carcinoma Analyst Views
  29. Urothelial Carcinoma Key Companies
  30. Appendix

 

For further information on the Urothelial Carcinoma Pipeline therapeutics, reach out to Urothelial Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market